Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) pandemic, global sequencing efforts have led in the field of inborn errors of immunity, and inspired particularly by previous research on life-threatening influenza, they have revealed that known and novel inborn errors affecting type I interferon immunity underlie critical COVID-19 in up to 5% of cases. In addition, neutralizing autoantibodies against type I interferons have been identified in up to 20% of patients with critical COVID-19 who are older than 80 years and 20% of fatal cases, with a higher prevalence in men and individuals older than 70 years. Also, inborn errors impairing regulation of type I interferon responses and RNA degradation have been found as causes of multisystem inflammatory syndrome in children, a life-threatening hyperinflammatory condition complicating otherwise mild initial SARS-CoV-2 infection in children and young adults. Better understanding of these immunologic mechanisms can aid in designing treatments for severe COVID-19, multisystem inflammatory syndrome in children, long COVID, and neuro-COVID.

Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children / Bucciol, G.; Abel, L.; Al-Muhsen, S.; Aiuti, A.; Al-Mulla, F.; Andreakos, E.; Antonio, N.; Arias, A. A.; Trouillet-Assant, S.; Belot, A.; Biggs, C. M.; Bousfiha, A. A.; Bolze, A.; Borghesi, A.; Brodin, P.; Christodoulou, J.; Cobat, A.; Condino-Neto, A.; Constantinescu, S.; Dalgard, C. L.; Espinosa-Padilla, S.; Fellay, J.; Flores, C.; Franco, J. L.; Froidure, A.; Gorochov, G.; Haerynck, F.; Halwani, R.; Hsieh, E. W. Y.; Itan, Y.; Kisand, K.; Lau, Y. -L.; Mansouri, D.; Meyts, I.; Mogensen, T. H.; Ng, L. F. P.; Notarangelo, L. D.; Novelli, G.; Okada, S.; Ozcelik, T.; Perez de Diego, R.; Prando, C.; Pujol, A.; Quintana-Murci, L.; Renia, L.; Resnick, I.; Roussel, L.; Rodriguez-Gallego, C.; Sancho-Shimizu, V.; Shahrooei, M.; Soler-Palacin, P.; Spaan, A. N.; Tancevski, I.; Tangye, S. G.; Tayoun, A. A.; Temel, S. G.; Tiberghien, P.; Tur, J. P.; Turvey, S. E.; Uddin, F.; Uddin, M. J.; Vidigal, M.; Vinh, D. C.; Zatz, M.; Okamoto, K.; Perlin, D. S.; Pesole, G.; Thorball, C.; van de Beek, D.; Colobran, R.; Wauters, J.; Zhang, S. -Y.; Zhang, Q.; Su, H. C.; Casanova, J. -L.. - In: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. - ISSN 0091-6749. - 151:4(2023), pp. 832-840. [10.1016/j.jaci.2023.02.003]

Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children

Aiuti A.;
2023-01-01

Abstract

Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) pandemic, global sequencing efforts have led in the field of inborn errors of immunity, and inspired particularly by previous research on life-threatening influenza, they have revealed that known and novel inborn errors affecting type I interferon immunity underlie critical COVID-19 in up to 5% of cases. In addition, neutralizing autoantibodies against type I interferons have been identified in up to 20% of patients with critical COVID-19 who are older than 80 years and 20% of fatal cases, with a higher prevalence in men and individuals older than 70 years. Also, inborn errors impairing regulation of type I interferon responses and RNA degradation have been found as causes of multisystem inflammatory syndrome in children, a life-threatening hyperinflammatory condition complicating otherwise mild initial SARS-CoV-2 infection in children and young adults. Better understanding of these immunologic mechanisms can aid in designing treatments for severe COVID-19, multisystem inflammatory syndrome in children, long COVID, and neuro-COVID.
2023
COVID-19
multisystem inflammatory syndrome in children
SARS-CoV-2
type I interferon
File in questo prodotto:
File Dimensione Formato  
Bucciol_JACI_2023.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Altra licenza
Dimensione 625.51 kB
Formato Adobe PDF
625.51 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/146699
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact